Literature DB >> 20408266

Penetrance of LRRK2 mutations in familial Parkinson disease.

.   

Abstract

Entities:  

Year:  2009        PMID: 20408266

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


× No keyword cloud information.
  1 in total

1.  The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Authors:  Jeanne C Latourelle; Mei Sun; Mark F Lew; Oksana Suchowersky; Christine Klein; Lawrence I Golbe; Margery H Mark; John H Growdon; G Frederick Wooten; Ray L Watts; Mark Guttman; Brad A Racette; Joel S Perlmutter; Anwar Ahmed; Holly A Shill; Carlos Singer; Stefano Goldwurm; Gianni Pezzoli; Michela Zini; Marie H Saint-Hilaire; Audrey E Hendricks; Sally Williamson; Michael W Nagle; Jemma B Wilk; Tiffany Massood; Karen W Huskey; Jason M Laramie; Anita L DeStefano; Kenneth B Baker; Ilia Itin; Irene Litvan; Garth Nicholson; Alastair Corbett; Martha Nance; Edward Drasby; Stuart Isaacson; David J Burn; Patrick F Chinnery; Peter P Pramstaller; Jomana Al-hinti; Anette T Moller; Karen Ostergaard; Scott J Sherman; Richard Roxburgh; Barry Snow; John T Slevin; Franca Cambi; James F Gusella; Richard H Myers
Journal:  BMC Med       Date:  2008-11-05       Impact factor: 8.775

  1 in total
  1 in total

Review 1.  Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.

Authors:  Gunjan Thakur; Vikas Kumar; Keun Woo Lee; Chungkil Won
Journal:  Genes (Basel)       Date:  2022-08-11       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.